Key2Brain AB
Developing proprietary technology for next-generation brain targeting therapeutics.
Oversigt
- 10–19
- Medarbejdere
- 2.5–5mio SEK
- Omsætning
- 2020
- Grundlagt
Beskrivelse
Key2Brain is a Swedish biotechnology company focused on developing next-generation therapies designed to treat severe diseases affecting the brain. Their core offering is a groundbreaking proprietary technology platform engineered to facilitate efficient uptake and broad distribution of therapeutics...
Tags
Nøgleord
Virksomhedsoplysninger
- Branche
- Bioteknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE559239874601
Beslutningstagere
Ingen beslutningstagere fundet endnu
Lignende virksomheder
20 lignende virksomheder i Funnelfeedr
AAX Biotech AB
5–9 medarbejdereResearch-driven biotech advancing antibody therapies via proprietary technology.
IRLAB Therapeutics AB
1–4 medarbejdereDeveloping novel CNS drugs for Parkinson's disease using proprietary technology.
Affibody AB
50–99 medarbejdereDeveloping next-generation radiopharmaceuticals using proprietary Affibody technology.
Uppsala Therapeutics AB
0 medarbejdereDeveloping nanoparticle platforms for targeted drug delivery across the BBB.
Grespo AB
0 medarbejdereYoung biomedical company developing CNS treatments based on 2-oxoglutarate research.
Udforsk mere
Spørgsmål om Key2Brain AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo